Yongqu Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yongqu Lu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fuchou Tang
Peking University
1 shared publication - Jie An
Marine engineering, Dalian Maritime University, Dalian 116026, China
1 shared publication - Jingwei Yang
Biomedical Pioneering Innovation Center, School of Life Sciences, Peking University , Beijing 100871
1 shared publication - Junpeng Gao
Biomedical Pioneering Innovation Center, School of Life Sciences, Peking University, Beijing, China
1 shared publication - Lehao Ren
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Li Zhang
Department of Infectious Diseases, Tianjin Medical University General Hospital, Tianjin, P.R. China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 22 June 2023
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (4) , 285-304
Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids
Colorectal cancer (CRC) is a highly heterogeneous cancer and exploring novel therapeutic options is a pressing issue that needs to be addressed. Here, we established human CRC tumor-derived organoids that well represent both morphological and molecular heterogeneities of original tumors. To efficiently identify repurposed drugs for CRC, we developed a robust organoid-based drug screening system. By combining the repurposed drug library and computation-based drug prediction, 335 drugs were tested and 34 drugs with anti-CRC effects were identified. More importantly, we conducted a detailed transcriptome analysis of drug responses and divided the drug response signatures into five representative patterns: differentiation induction, growth inhibition, metabolism inhibition, immune response promotion, and cell cycle inhibition. The anticancer activities of drug candidates were further validated in the established patient-derived organoids-based xenograft (PDOX) system in vivo. We found that fedratinib, trametinib, and bortezomib exhibited effective anticancer effects. Furthermore, the concordance and discordance of drug response signatures between organoids in vitro and pairwise PDOX in vivo were evaluated. Our study offers an innovative approach for drug discovery, and the representative transcriptome features of drug responses provide valuable resources for developing novel clinical treatments for CRC.
- 22 June 2023
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (4) , 285-304
Top Cited PapersOpen AccessDrug repurposing screening and mechanism analysis based on human colorectal cancer organoids
Colorectal cancer (CRC) is a highly heterogeneous cancer and exploring novel therapeutic options is a pressing issue that needs to be addressed. Here, we established human CRC tumor-derived organoids that well represent both morphological and molecular heterogeneities of original tumors. To efficiently identify repurposed drugs for CRC, we developed a robust organoid-based drug screening system. By combining the repurposed drug library and computation-based drug prediction, 335 drugs were tested and 34 drugs with anti-CRC effects were identified. More importantly, we conducted a detailed transcriptome analysis of drug responses and divided the drug response signatures into five representative patterns: differentiation induction, growth inhibition, metabolism inhibition, immune response promotion, and cell cycle inhibition. The anticancer activities of drug candidates were further validated in the established patient-derived organoids-based xenograft (PDOX) system in vivo. We found that fedratinib, trametinib, and bortezomib exhibited effective anticancer effects. Furthermore, the concordance and discordance of drug response signatures between organoids in vitro and pairwise PDOX in vivo were evaluated. Our study offers an innovative approach for drug discovery, and the representative transcriptome features of drug responses provide valuable resources for developing novel clinical treatments for CRC.
- 1 March 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (1) , 125-131
MMP9 is involved in HO-1-mediated upregulation of apical junctional complex in Caco-2 cells under oxygen-glucose deprivation
- 1 March 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 498 (1) , 125-131
MMP9 is involved in HO-1-mediated upregulation of apical junctional complex in Caco-2 cells under oxygen-glucose deprivation